New AI Tool Predicts Most Common Brain Tumor Recurrence Without Advanced Genetic Testing

Researchers at Mayo Clinic have developed an artificial intelligence tool that can predict recurrence risk in meningiomas, the most common primary brain tumor in adults, using only routine histopathology images. This breakthrough eliminates the need for expensive advanced genetic testing, potentially making risk assessment more accessible and affordable for patients. Meningiomas account for about 30% of all primary brain tumors, and accurate recurrence prediction helps guide treatment decisions and follow-up care. The AI-powered approach could significantly reduce healthcare costs while expanding access to personalized prognostic information across diverse populations, including those in underserved communities like Puerto Rico.